Genetic Polymorphism of Vitamin K Epoxide Reductase (VKORC1) 1173C>T in a Chinese and a Caucasian Population
Open Access
- 15 May 2006
- journal article
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 98 (6), 611-613
- https://doi.org/10.1111/j.1742-7843.2006.pto_440.x
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Effect ofVKORC1Haplotypes on Transcriptional Regulation and Warfarin DoseNew England Journal of Medicine, 2005
- A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivityHuman Molecular Genetics, 2005
- Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivityBlood, 2005
- A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarinBlood, 2005
- Pharmacogenetics of acenocoumarol pharmacodynamicsClinical Pharmacology & Therapeutics, 2004
- Detection of genotyping errors by Hardy–Weinberg equilibrium testingEuropean Journal of Human Genetics, 2004
- Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2Nature, 2004
- Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populationsFundamental & Clinical Pharmacology, 2003
- Population differences in S‐warfarin metabolism between CYP2C9 genotype‐matched Caucasian and Japanese patientsClinical Pharmacology & Therapeutics, 2003
- Factors determining the maintenance dose of warfarin in Chinese patientsQJM: An International Journal of Medicine, 1996